Combined preparations for the treatment of cancer
Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.
1. A method of treating or ameliorating cancer, which comprises:
administering to a subject in need of such treatment or amelioration a derivative of LAG-3 protein that is able to bind to MHC class II molecules, wherein the derivative is IMP321, and an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor; and
synergistically reducing tumor growth in the subject, the synergistic reduction of tumor growth being more than a sum of a reduction of tumor growth caused by administration to the subject of the derivative alone and the anti-neoplastic agent alone.
2. A method according to claim 1 , wherein the derivative and the anti-neoplastic agent are administered sequentially to the subject.
3. A method according to claim 1 , wherein the derivative is administered after the anti-neoplastic agent.
4. A method according to claim 2 , wherein the derivative and the anti-neoplastic agent are administered to the subject within 96 hours of each other.
5. A method according to claim 1 , wherein the derivative and the anti-neoplastic agent are co-administered to the subject.
6. A method according to claim 1 , wherein the derivative is administered to the subject at a dose of 0.25-30 mg per individual.
7. A method according to claim 1 , wherein a plurality of doses of the derivative is administered to the subject.
8. A method according to claim 1 , wherein a plurality of doses of the anti-neoplastic agent is administered to the subject.
9. A method according to claim 7 , wherein a dose of the derivative is administered before, with, or after each administration of two or more doses of the anti-neoplastic agent.
10. A method according to claim 1 , wherein the platinum-based anti-neoplastic agent comprises oxaliplatin or carboplatin.
11. A method according to claim 1 , wherein the topoisomerase I inhibitor comprises topotecan.
12. A method according to claim 1 , wherein the anti-neoplastic agent is selected from the group consisting of oxaliplatin, carboplatin, and topotecan.
13. A method according to claim 1 , wherein the anti-neoplastic agent is oxaliplatin.
14. A method according to claim 1 , wherein the anti-neoplastic agent is carboplatin.
15. A method of treating or ameliorating a cancer in a subject administered an anti-neoplastic agent, and in need thereof, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor, which comprises:
administering an effective amount of a derivative of LAG-3 protein that is able to bind to MHC class II molecules; to the subject, wherein the derivative is IMP321; and
synergistically reducing tumor growth in the subject,
the synergistic reduction of tumor growth being more than a sum of a reduction of tumor growth caused by administration to the subject of the derivative alone and the anti-neoplastic agent alone.
16. A method according to claim 15 , wherein the anti-neoplastic agent is selected from the group consisting of oxaliplatin, carboplatin, and topotecan.
17. A method according to claim 15 , wherein the anti-neoplastic agent is oxaliplatin.
18. A method according to claim 15 , wherein the anti-neoplastic agent is carboplatin.
19. A method according to claim 15 , wherein the anti-neoplastic agent is topotecan.
20. A method of treating or ameliorating a cancer in a subject administered a derivative of LAG-3 protein that is able to bind to MHC class II molecules, and in need thereof, wherein the derivative is IMP321, which comprises:
administering an effective amount of an anti-neoplastic agent to the subject, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor; and
synergistically reducing tumor growth in the subject,
the synergistic reduction of tumor growth being more than a sum of a reduction of tumor growth caused by administration to the subject of the derivative alone and the anti-neoplastic agent alone.
21. A method according to claim 20 , wherein the anti-neoplastic agent is selected from the group consisting of oxaliplatin, carboplatin, and topotecan.
22. A method according to claim 20 , wherein the anti-neoplastic agent is oxaliplatin.
23. A method according to claim 20 , wherein the anti-neoplastic agent is carboplatin.
24. A method according to claim 20 , wherein the anti-neoplastic agent is topotecan.
25. A combined preparation for enhancing a reduction of tumor growth, which comprises: (a) a derivative of LAG-3 protein that is able to bind to MHC class II molecules, wherein the derivative is IMP321; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor, the derivative and the anti-neoplastic agent causing a synergistic reduction of tumor growth when administered to a subject in need thereof, the synergistic reduction of tumor growth being more than a sum of a reduction of tumor growth caused by administration to the subject of the derivative alone and the anti-neoplastic agent alone.
26. A combined preparation according to claim 25 , for co-administration or sequential administration of the derivative and the anti-neoplastic agent.
27. A combined preparation according to claim 25 , wherein the derivative is separate from the anti-neoplastic agent.
28. A combined preparation according to claim 25 , wherein the derivative is present in the amount of 0.25-30 mg.
29. A combined preparation according to claim 25 , which comprises a plurality of doses of the derivative.
30. A combined preparation according to claim 25 , which comprises a plurality of doses of the anti-neoplastic agent.
31. A combined preparation according to claim 25 , wherein the platinum-based anti-neoplastic agent comprises oxaliplatin or carboplatin.
32. A combined preparation according to claim 25 , wherein the topoisomerase I inhibitor comprises topotecan.
33. A combined preparation according to claim 25 , wherein the anti-neoplastic agent is selected from the group consisting of oxaliplatin, carboplatin, and topotecan.
34. A combined preparation according to claim 25 , wherein the anti-neoplastic agent is oxaliplatin.
35. A combined preparation according to claim 25 , wherein the anti-neoplastic agent is carboplatin.
36. A pharmaceutical composition for enhancing a reduction of tumor growth, which comprises: (a) a derivative of LAG-3 protein that is able to bind to MHC class II molecules, wherein the derivative is IMP321; (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor; and (c) a pharmaceutically acceptable carrier, excipient, or diluent, the derivative, and the anti-neoplastic agent causing a synergistic reduction of tumor growth when administered to a subject in need thereof, the synergistic reduction of tumor growth being more than a sum of a reduction of tumor growth caused by administration to the subject of the derivative alone and the anti-neoplastic agent alone.
37. A pharmaceutical composition according to claim 36 , wherein the anti-neoplastic agent is selected from the group consisting of oxaliplatin, carboplatin, and topotecan.
38. A pharmaceutical composition according to claim 36 , wherein the anti-neoplastic agent is oxaliplatin.
39. A pharmaceutical composition according to claim 36 , wherein the anti-neoplastic agent is carboplatin.
40. A pharmaceutical composition according to claim 36 , wherein the anti-neoplastic agent is topotecan.